Desktop Site |
19 Apr 24 | 14:21 | Open
Equity SME Eq Drv Currency Commodity Corporates
Get Quote
Notices |
S&P BSE SENSEX 73,014.28 +525.29 +0.72 %
Corporate Announcement
  • Security Code532296
    CompanyGLENMARK PHARMACEUTICALS LTD.
    Exchange Received Time08/11/2018 11:02:24
    Exchange Disseminated Time08/11/2018 11:02:32
    Time Taken00:00:08
     
     
     Announcement under Regulation 30 (LODR)-Press Release / Media Release | 11/08/18 11:02 
     Sub: Glenmark Pharmaceuticals Announces Decision to Launch Phase 1 Trial in Solid Tumors for its CD38xCD3 Bispecific Antibody GBR 1342 Based on Human Translational Data

    With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.
    		 
    AttachmentDownload PDF
     
    << Back  
     
Recently Viewed
Copyright@ 2015. All Rights Reserved. BSE Ltd.
(42) 19 Apr 24|14:21 (IST)